Kyverna Financial Statements From 2010 to 2026

KYTX Stock   7.93  0.66  9.08%   
Kyverna Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kyverna Therapeutics' valuation are provided below:
Gross Profit
-137.2 M
Market Capitalization
433.3 M
Enterprise Value Revenue
3.3 K
Earnings Share
(3.73)
We have found one hundred seventeen available fundamental ratios for Kyverna Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of Kyverna Therapeutics last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road.
Check Kyverna Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kyverna Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 18.4 M, Interest Income of 18.5 M or Depreciation And Amortization of 1.5 M, as well as many indicators such as Price To Sales Ratio of 136, Dividend Yield of 0.0 or PTB Ratio of 0.46. Kyverna financial statements analysis is a perfect complement when working with Kyverna Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Kyverna Stock
Check out the analysis of Kyverna Therapeutics Correlation against competitors.

Kyverna Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets367.9 M350.3 M128.9 M
Slightly volatile
Short and Long Term Debt Total9.2 M9.5 M6.7 M
Slightly volatile
Other Current Liabilities14.9 M29 M11.2 M
Slightly volatile
Total Current Liabilities22.4 M38.8 M18.7 M
Slightly volatile
Property Plant And Equipment Net11.4 M12.3 M8.9 M
Slightly volatile
Current Deferred Revenue8.3 M10.4 M6.9 M
Slightly volatile
Accounts Payable3.1 M5.3 M1.7 M
Slightly volatile
Cash67.4 M111.1 M74.1 M
Very volatile
Non Current Assets Total14.4 M18.3 M10.5 M
Slightly volatile
Non Currrent Assets OtherM6.1 M1.6 M
Slightly volatile
Cash And Short Term Investments345.3 M328.9 M116.6 M
Slightly volatile
Common Stock Shares Outstanding41.9 M44.1 M66.7 M
Slightly volatile
Liabilities And Stockholders Equity367.9 M350.3 M128.9 M
Slightly volatile
Non Current Liabilities Total3.7 M3.9 M83.3 M
Slightly volatile
Capital Lease Obligations9.2 M9.5 M6.7 M
Slightly volatile
Other Current Assets2.9 M5.3 M1.8 M
Slightly volatile
Other Stockholder Equity640 M609.5 M105.4 M
Slightly volatile
Total Liabilities43.2 M34.3 M102.5 M
Slightly volatile
Property Plant And Equipment Gross13.8 M16.5 M10.3 M
Slightly volatile
Total Current Assets350.9 M334.2 M118.5 M
Slightly volatile
Non Current Liabilities Other5.1 K5.4 K56.7 K
Slightly volatile
Net Working Capital310.1 M295.4 M98.7 M
Slightly volatile
Short Term Debt2.7 M4.5 M1.5 M
Slightly volatile

Kyverna Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income18.5 M17.7 M3.2 M
Slightly volatile
Depreciation And Amortization1.5 M2.5 M934.2 K
Slightly volatile
Interest Expense109.2 K163.3 K41.3 K
Slightly volatile
Selling General Administrative36.4 M34.7 M11.5 M
Slightly volatile
Other Operating Expenses172.2 M164 M56.6 M
Slightly volatile
Research Development135.8 M129.3 M45 M
Slightly volatile
Cost Of Revenue1.5 M2.5 M934.2 K
Slightly volatile
Total Operating Expenses169.6 M161.5 M56 M
Slightly volatile
Reconciled Depreciation1.5 M2.5 M934.2 K
Slightly volatile

Kyverna Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.2 M9.6 M6.7 M
Pretty Stable
Begin Period Cash Flow35.5 M31.7 M32.2 M
Slightly volatile
Depreciation1.5 M2.5 M934.2 K
Slightly volatile
Capital Expenditures1.3 M2.5 M1.3 M
Pretty Stable
Issuance Of Capital Stock412 M392.3 M122.8 M
Slightly volatile
Total Cash From Financing Activities407.1 M387.7 M121.9 M
Slightly volatile
End Period Cash Flow68 M111.7 M74.7 M
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio136127132
Slightly volatile
Stock Based Compensation To Revenue0.140.150.9452
Slightly volatile
Capex To Depreciation1.191.03381.8179
Slightly volatile
EV To Sales127122121
Slightly volatile
Payables Turnover0.340.420.3944
Pretty Stable
Sales General And Administrative To Revenue0.891.031.0816
Pretty Stable
Research And Ddevelopement To Revenue4.744.654.4922
Slightly volatile
Capex To Revenue0.190.130.199
Slightly volatile
Cash Per Share7.056.713.4511
Slightly volatile
Days Payables Outstanding948910923
Slightly volatile
Income Quality1.061.030.8938
Slightly volatile
Net Debt To EBITDA1.330.812.1828
Slightly volatile
Current Ratio4.197.755.0668
Slightly volatile
Capex Per Share0.0380.06610.0466
Pretty Stable
Revenue Per Share0.20.250.2292
Slightly volatile
Interest Debt Per Share0.230.250.2182
Very volatile
Debt To Assets0.02960.03110.0674
Very volatile
Days Of Payables Outstanding948910923
Slightly volatile
Ebt Per Ebit1.061.030.9963
Very volatile
Quick Ratio4.197.755.0668
Slightly volatile
Cash Ratio3.443.294.2236
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.171.0618
Pretty Stable
Fixed Asset Turnover0.70.650.6904
Slightly volatile
Debt Ratio0.02960.03110.0674
Very volatile
Price Sales Ratio136127132
Slightly volatile
Asset Turnover0.06850.09450.0748
Slightly volatile

Kyverna Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap114.7 M129 M140.8 M
Slightly volatile
Enterprise Value44 M49.5 M54 M
Slightly volatile

Kyverna Fundamental Market Drivers

About Kyverna Therapeutics Financial Statements

Kyverna Therapeutics investors use historical fundamental indicators, such as Kyverna Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Kyverna Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue10.4 M8.3 M
Cost Of Revenue2.5 M1.5 M
Stock Based Compensation To Revenue 0.15  0.14 
Sales General And Administrative To Revenue 1.03  0.89 
Research And Ddevelopement To Revenue 4.65  4.74 
Capex To Revenue 0.13  0.19 
Revenue Per Share 0.25  0.20 
Ebit Per Revenue(3.76)(3.95)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Kyverna Stock Analysis

When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.